As of November 19, 2024, ProPhase Labs, Inc. had a $18.1 million market capitalization, putting it in the 10th percentile of companies in the Pharmaceuticals industry. ProPhase Labs, Inc. does not ...

ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. These ...

Reports Q3 revenue $3.146M vs $8.365M last year. Ted Karkus, ProPhase Labs (PRPH)’ Chief Executive Officer, commented: “Q3 2024 showcased the significant potential of our subsidiaries.

GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase” or the "Company”), a next-generation biotech, genomics and diagnostics company, today announced the ...

04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced the launch of ...

GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and ...

Dramatic change in chromosomal DNA morphology between interphase and mitosis is a defining features of the eukaryotic cell cycle. Two types of enzymes, namely cohesin and condensin confer the topology ...

In conclusion, Miranda transitions from a uniformly cortical localization with low intensity levels in interphase, to a basal localization with high intensity levels in metaphase (Figure 1B,B’, C).